

On-line Table: Summary of patient characteristics and follow-up results

Branch Vessel Arising from														
Age (yr)		Sex	Location	Size (mm)	Aneurysm Dome	Dual Antiplatelet Regimen	Complications	First Follow-Up (mo)	% Occlusion	Last Follow-Up (mo)	% Occlusion	Time to Occlusion	Retreatment	% Occlusion after Retreatment
Patients with spontaneous occlusion during follow-up														
1	64	F	R PO	7.1	Yes	ASA 325 mg + clopidogrel 75 mg	No	5.4	<90	42.2	100	42.2	NA	NA
2	53	F	L PO	6.6	No	ASA 81mg + ticagrelor 90 mg BID	No	6.3	<90	11.9	100	11.9	NA	NA
Patients with residual filling and collar sign at last follow-up, without intervention														
3	61	F	L MCA	20.6	Yes	ASA 81mg + ticagrelor 90 mg BID	No	5.7	<90	31.5	<90	NA	NA	NA
4	34	F	L ICAB	11.5	Yes	ASA 81mg + ticagrelor 90 mg BID	No	6.5	<90	33	<90	NA	NA	NA
5	71	M	L PO	6.6	Yes	ASA 325 mg + clopidogrel 75 mg	No	4.2	<90	27.9	<90	NA	NA	NA
6		M	R PO	4.6	Yes	ASA 325 mg + clopidogrel 75 mg	No	6.8	<90	23.7	<90	NA	NA	NA
7	44	F	L PO	3.2	No	ASA 81mg + ticagrelor 90 mg BID	No	7.2	<90	34.5	<90	NA	NA	NA
8	55	F	R PO	10.5	No	ASA 81mg + ticagrelor 90 mg BID	No	6.2	<90	24.3	<90	NA	NA	NA
9		F	L PO	5.5	Yes	ASA 81mg + ticagrelor 90 mg BID	No	6.0	<90	18	<90	NA	NA	NA
Patients with occlusion during follow-up after a 2nd PED														
10	44	F	R PO	6.5	No	ASA 325 mg + clopidogrel 75 mg	No	6.0	<90	36.1	100	36.1	2nd PED at 24 mo	100
Patients with residual filling and collar sign at last follow-up after a 2nd PED														
11	66	F	L PO	4.5	Yes	ASA 81 mg + ticagrelor 90 mg BID	No	4.3	<90	42.7	<90	NA	2nd PED at 33.4 mo	<90
12	31	F	R PO	3.9	Yes	ASA 81mg + ticagrelor 90 mg BID	No	4.2	<90	41.8	<90	NA	2nd PED at 15.1mo	<90
13	55	F	R PO	6.1	Yes	ASA 325 mg + clopidogrel 75 mg	No	5.7	<90	42.3	<90	NA	2nd PED at 18.1 and 3rd at 30.4 mo	<90
14	62	F	R PcomA	7.3	Yes	ASA 325 mg + clopidogrel 75 mg	No	6.3	<90	15.8	<90	NA	2nd PED at 15.8 mo	NA ^a
15	81	F	L MCA	12.1 ^b	No	ASA 81 mg + prasugrel 10 mg	No	6.8	<90	12.6	<90	NA	2nd PED at 6.8 mo	<90
16	49	F	L PO	1.9	Yes	ASA 81 mg + prasugrel 10 mg	No	6.7	100	45.2	<90	NA	2nd PED at 21mo	<90
17	40	F	L PO	5.4	Yes	ASA 81 mg + prasugrel 10 mg	No	6.0	<90	34.9	<90	NA	2nd PED at 11 mo	<90
18	46	F	L PO	7	Yes	ASA 81mg + ticagrelor 90 mg BID	No	4.9	<90	32.4	<90	NA	2nd PED at 10.7 mo	<90
19	67	F	L PO	6.1	Yes	ASA 81mg + ticagrelor 90 mg BID	No	6.0	<90	32.9	<90	NA	2nd PED at 15.8 mo	<90

Note:—ICAB indicates internal carotid artery bifurcation; PO, paraphthalmic; PcomA, posterior communicating artery; BID, two times per day; R, right; L, left; ASA, acetylsalicylic acid; NA, not applicable.

^a Patient died 1 month after treatment from an unrelated cause.

^b Patient with thrombosed aneurysm and subsequent growth during follow-up.